Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of hydrocodone bitartrate extended-release (CEP-33237) for moderate-to-severe chronic pain due to osteoarthri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain
• Osteoarthritis

Drugs mentioned

• Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) (Hydrocodone bitartrate extended-release)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Pain | Phase 3 | Status: COMPLETED | Results posted: 2017-06-05